Findings hint that vaccination of pregnant women might also protect their newborns.
Antibodies to the SARS-CoV-2 coronavirus in the blood of pregnant women cross the placenta efficiently and are were found at similar concentrations in the blood of their newborns, according to a large study from researchers at the Perelman School of Medicine at the University of Pennsylvania.
The findings, reported JAMA Pediatrics, suggest that mothers who have had COVID-19, or asymptomatic exposure to the coronavirus, can, through this antibody transfer, provide some protection against the virus to their newborns. The authors hypothesize that this may have implications for COVID-19 vaccines.
The researchers tested blood samples from 1,471 women and their newborns for the presence of antibodies to SARS-CoV-2, and observed that 83 of the women had significant levels of SARS-CoV-2-specific antibodies. The vast majority (87 percent) of the newborn babies of these women also had significant levels of SARS-CoV-2-specific antibodies in samples of umbilical cord blood drawn at birth. The study found no evidence that the antibodies were due to fetal infection, indicating that it is likely the antibodies crossed the placenta from the mother’s blood to the fetal circulation.
“This transfer appears to be pretty efficient,” said study co-senior author Karen Puopolo, MD, PhD, a neonatologist at Children’s Hospital of Philadelphia, an associate professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine and Chief of the Section on Newborn Medicine at Pennsylvania Hospital. “In some of the cases, the newborn’s blood concentration of SARS-CoV-2 antibodies was even higher than the mother’s.”
“In general, our findings are consistent with what we know about cross-placental transfer of antibodies to other viruses, and should contribute to the discussion about whether and when to vaccinate pregnant women against SARS-CoV-2,” said co-senior author Scott Hensley, PhD, an associate professor of Microbiology at Penn Medicine and a member of the Penn Institute for Immunology.
Prior, smaller studies also have found evidence that maternal antibodies can cross the placenta to the fetal bloodstream. However, the dynamics and the efficiency of this transfer have been unclear.
Puopolo and Hensley and their colleagues used a previously validated blood test kit to check for SARS-CoV-2-specific antibodies in blood serum samples collected at the time of delivery during a four-month period from April to August of last year at Pennsylvania Hospital in Philadelphia. The study in all covered 1,471 mother-and-child pairs of samples.
About 6 percent of the women, 83 in all, showed significant SARS-CoV-2 antibody levels on the tests. Of their 83 newborns, 72 (87 percent) also showed significant SARS-CoV-2 antibody levels.
The researchers found that the most common class of antibodies in the blood, known as immunoglobulin G (IgG) antibodies, appeared to transfer readily from the mother’s blood across the placenta. IgG anti-SARS-CoV-2 levels detected in the newborns closely tracked levels in their mothers.
However, a class of larger antibodies, known as IgM antibodies, which tend to be produced earlier in an infection and are not known to cross the placenta, were not detected in any cord blood sample. Since infants have some ability to produce their own IgM antibodies, the absence of these antibodies also suggested that the SARS-CoV-2 virus itself had not crossed the placenta and infected them. Among the mothers who had anti-SARS-CoV-2 antibodies but their infants didn’t, 5 had only IgM antibodies, which would not have been expected to cross the placenta. The other 6 had low levels of IgG antibodies. COVID-19 vaccines are generally designed to elicit high levels of IgG antibodies against the virus.
The transport of IgG antibodies across the placenta is known to occur especially in the third trimester of pregnancy, and as more time passes, more antibodies cross. Scientists also know that an infection with a novel virus can take time to elicit a significant antibody response. The results from Hensley, Puopolo and their colleagues were consistent with these known patterns: placental transfer was greater the longer the time elapsed between maternal COVID-19 infection and delivery.
Other co-authors of the study were co-first authors Dustin Flannery and Sigrid Gouma; and Miren Dhudasia, Sagori Mukhopadhyay, Madeline Pfeifer, Emily Woodford, Jourdan Triebwasser, Jeffrey Gerber, Jeffrey Morris, Madison Weirick, Christopher McAllister, Marcus Bolton, Claudia Arevalo, Elizabeth Anderson, and Eileen Goodwin.
Funding was provided by the Children’s Hospital of Philadelphia Foerderer Grant for Excellence and philanthropic support from Philadelphia 76ers star player Joel Embiid and managing partners Josh Harris and David Blitzer, and Philadelphia Eagles owner Jeffrey Lurie.
Reference: Dustin D. Flannery, Sigrid Gouma, Miren B. Dhudasia, Sagori Mukhopadhyay, Madeline R. Pfeifer, Emily C. Woodford, Jourdan E. Triebwasser, Jeffrey S. Gerber, Jeffrey S. Morris, Madison E. Weirick, Christopher M. McAllister, Marcus J. Bolton, Claudia P. Arevalo, Elizabeth M. Anderson, Eileen C. Goodwin, Scott E. Hensley, Karen M. Puopolo, “Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios”, JAMA Pediatr. Published online January 29, 2021. doi:10.1001/jamapediatrics.2021.0038
Provided by Penn Medicine
About Penn Medicine
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.6 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.